CEO Rob Fried details Niagen Bioscience’s NAD+ business and April 28 telehealth launch in an exclusive interview with LA Times Studios.
Niagen Bioscience spent decades following the science on NAD+ before anyone was buying. Now, with a profitable consumer business, new bets on at-home injections, topicals, and potentially beverages, it appears to have timed the longevity boom perfect… [10085 chars]
Source: Los Angeles Times | Published: 2026-04-19T10:00:00Z
Credit: Los Angeles Times
